Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Migraine (Nov 2018)

Posted by Matt Breese on Nov 16, 2018

Find me on:

According to our recent payer coverage analysis for migraine treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for migraine treatments shows that about 42% of the covered lives under commercial formularies are restricted.

MMIT-Reality Check-Migraine_4Q2018

Data snapshot as of Q4 2018

Trends: The launch of the CGRP inhibitors disrupts the current market dynamics, and it's currently unclear if they will create a treatment step after generic products but before botulinum toxins or be treated roughly equal to botulinum toxins. Via AIS Health.

To read the full Reality Check on Migraine treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing